Adial Pharmaceuticals Inc (ADIL) Stock Price, Quote & News

Company Profile

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen...

Industry: Biotechnology

Sector: Healthcare

Phone: 804 487 8196

Website: www.adial.com

Address:

4870 Sadler Road, Suite 300, Glen Allen, United States

StayPresent Jun. 3 at 11:22 PM

$ADIL straight down since RS. True Value is 9 pennies. Pathetic.

0 · Reply

Mikemelga2024 Jun. 3 at 2:50 PM

$ADIL dead stock

0 · Reply

Patrik605 Jun. 3 at 2:44 PM

$ADIL People entrust money to this company for a year just to dilute the shares for their wages and absolutely zero progress.

0 · Reply

Patrik605 Jun. 3 at 2:30 PM

$ADIL No news again! They will destroy absolutely all possible potential with their total incompetence. They have 10 months without any progress! Especially since they said they wanted to start the phase at the end of 2025! Liars. They have done almost nothing in 10 months! Their finances are small, their wages are exorbitantly high (see Carry) and there are no results!

1 · Reply

skyrockets_Inc Jun. 1 at 3:35 PM

$ADIL For the longs here, what is the theory of what is happening here? Stock seems to be slow grinding for no apparent reason...

1 · Reply

Patrik605 Jun. 1 at 1:41 PM

$ADIL Hey, will we hear any progress? Any results from these employees and the company? Since August of last year, a lot of cash has been burned and progress is almost zero. If you want, I'll create a forum for you that you're looking for investors and you can take a vacation again in peace....

0 · Reply

Pagal22 May. 30 at 4:12 PM

$ADIL

0 · Reply

StayPresent May. 29 at 9:23 PM

$ADIL was Claiborne a DEI hire or something? That brother been getting paid for doing nothing for years.

3 · Reply

Mikemelga2024 May. 29 at 5:02 PM

$ADIL NO VOLUME

0 · Reply

uptrend2025 May. 28 at 7:22 PM

$ADIL This is a miracle. Looks like it is under accumulation.

0 · Reply

Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update

2026-04-29T16:56:08.000Z - 5 weeks ago

Adial Pharmaceuticals files AD04 utility application with USPTO

Apr 29, 2026, 9:07 AM EDT - 5 weeks ago

Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045

2026-04-27T13:29:38.000Z - 5 weeks ago

Adial submits AD04 product application for FDA CNPV pilot program

Apr 27, 2026, 8:47 AM EDT - 5 weeks ago

Adial Pharmaceuticals Submits Application to FDA Commissioner's National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program

2026-04-22T13:57:56.000Z - 6 weeks ago

Adial Pharmaceuticals completes AD04 demonstration batch production

Apr 22, 2026, 9:35 AM EDT - 6 weeks ago

Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial

2026-03-06T13:06:13.000Z - 3 months ago

Adial Pharmaceuticals expects cash to fund operations into 2H of 2026

2026-03-03T13:35:20.000Z - 3 months ago

Adial Pharmaceuticals enters collaboration framework agreement with Molteni

2026-02-24T14:07:23.000Z - 3 months ago

Adial Pharmaceuticals regains compliance with Nasdaq listing requirement

Feb 24, 2026, 9:00 AM EST - 3 months ago

Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement

2026-02-23T13:48:10.000Z - 3 months ago

Adial Pharmaceuticals highlights recent FDA policy, may reduce trial burden

Feb 23, 2026, 8:30 AM EST - 3 months ago

Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One

2026-02-11T13:46:03.000Z - 4 months ago

Adial Pharmaceuticals price target lowered to $8 from $37.50 at Maxim

2026-02-06T00:50:11.000Z - 4 months ago

Adial Pharmaceuticals trading halted, news pending

2026-02-05T14:38:47.000Z - 4 months ago

Why Is Adial Pharmaceuticals Stock (ADIL) Down Today?

Feb 4, 2026, 9:35 AM EST - 4 months ago

Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04

2026-02-03T22:05:26.000Z - 4 months ago

Adial Pharmaceuticals announces 1-for-25 reverse stock split

Feb 3, 2026, 4:05 PM EST - 4 months ago

Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

2026-01-14T14:05:52.000Z - 5 months ago

Adial announces publication of international patent application for AD04

2025-11-26T13:05:42.000Z - 6 months ago

Adial Pharmaceuticals announces $2.86M warrant inducement transaction

2025-11-14T13:35:16.000Z - 7 months ago

Adial Pharmaceuticals reports Q3 net loss $1.8M vs $2.2M last year

Oct 17, 2025, 9:00 AM EDT - 8 months ago

Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show

2025-10-09T12:40:33.000Z - 8 months ago

Adial Pharmaceuticals partners with Genomind for Precision Medicine Testing

Oct 9, 2025, 8:30 AM EDT - 8 months ago

Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution

2025-09-30T11:40:10.000Z - 8 months ago

Adial Pharmaceuticals upgraded to Buy from Hold at Maxim

2025-09-16T12:16:04.000Z - 9 months ago

Adial announces receipt of final meeting minuts from EOP2 meeting with FDA

Sep 16, 2025, 8:00 AM EDT - 9 months ago

Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04

2025-09-03T12:41:40.000Z - 9 months ago

Adial granted a 180 calendar day extension by Nasdaq to regain compliance

Sep 3, 2025, 8:30 AM EDT - 9 months ago

Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule

Aug 14, 2025, 8:30 AM EDT - 10 months ago

Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 8:00 AM EDT - 10 months ago

Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting

Jul 16, 2025, 8:30 AM EDT - 11 months ago

Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders' Equity Listing Requirement

Jul 9, 2025, 8:30 AM EDT - 11 months ago

Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045

Jun 25, 2025, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply

May 15, 2025, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

May 2, 2025, 11:48 AM EDT - 1 year ago

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

May 1, 2025, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders

Mar 4, 2025, 8:30 AM EST - 1 year ago

Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

Feb 25, 2025, 9:00 AM EST - 1 year ago

Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

Feb 19, 2025, 9:00 AM EST - 1 year ago

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

Feb 12, 2025, 9:00 AM EST - 1 year ago

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

Jan 29, 2025, 9:00 AM EST - 1 year ago

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Dec 3, 2024, 8:30 AM EST - 1 year ago

Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations

Nov 5, 2024, 8:30 AM EST - 1 year ago

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

Sep 19, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Sep 4, 2024, 9:00 AM EDT - 1 year ago

Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 7, 2024, 9:00 AM EDT - 1 year ago

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Jul 31, 2024, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044

Jul 23, 2024, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Jun 20, 2024, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder

May 29, 2024, 8:30 AM EDT - 2 years ago

Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th

May 15, 2024, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 22, 2024, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office

Apr 10, 2024, 2:15 PM EDT - 2 years ago

Adial Pharmaceuticals posts promising update on alcohol disorder drug

Apr 10, 2024, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

Apr 2, 2024, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update

Mar 1, 2024, 7:00 PM EST - 2 years ago

Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds

Feb 28, 2024, 9:30 AM EST - 2 years ago

Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office

Feb 15, 2024, 9:00 AM EST - 2 years ago

Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20

Feb 13, 2024, 9:15 AM EST - 2 years ago

Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office

Jan 18, 2024, 8:30 AM EST - 2 years ago

Adial Announces Appointment of Tony Goodman as Chief Operating Officer

Dec 20, 2023, 9:00 AM EST - 2 years ago

Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate

Nov 29, 2023, 4:05 PM EST - 2 years ago

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement

Nov 14, 2023, 5:02 PM EST - 2 years ago

Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 31, 2023, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine Conference

StayPresent Jun. 3 at 11:22 PM

$ADIL straight down since RS. True Value is 9 pennies. Pathetic.

0 · Reply

Mikemelga2024 Jun. 3 at 2:50 PM

$ADIL dead stock

0 · Reply

Patrik605 Jun. 3 at 2:44 PM

$ADIL People entrust money to this company for a year just to dilute the shares for their wages and absolutely zero progress.

0 · Reply

Patrik605 Jun. 3 at 2:30 PM

1 · Reply

skyrockets_Inc Jun. 1 at 3:35 PM

$ADIL For the longs here, what is the theory of what is happening here? Stock seems to be slow grinding for no apparent reason...

1 · Reply

Patrik605 Jun. 1 at 1:41 PM

0 · Reply

Pagal22 May. 30 at 4:12 PM

$ADIL

0 · Reply

StayPresent May. 29 at 9:23 PM

$ADIL was Claiborne a DEI hire or something? That brother been getting paid for doing nothing for years.

3 · Reply

Mikemelga2024 May. 29 at 5:02 PM

$ADIL NO VOLUME

0 · Reply

uptrend2025 May. 28 at 7:22 PM

$ADIL This is a miracle. Looks like it is under accumulation.

0 · Reply

Zskylar May. 28 at 3:23 PM

$ADIL push

0 · Reply

tommy_john May. 27 at 10:40 PM

$ADIL the time is now!!!

0 · Reply

skyrockets_Inc May. 26 at 5:23 PM

$ADIL

0 · Reply

Patrik605 May. 26 at 3:57 PM

$ADIL Since August last year, their progress has been zero! Absolutely nothing. Only in April this year did they start to wake up and after the management was given shares for free for they employees, Of course, after the Split reversal and after their inaction and incompetence destroyed the stock's value by 90% in a year!, did they start doing something!

1 · Reply

Patrik605 May. 26 at 2:45 PM

$ADIL They really take their time... Another vacation? Incompetent and slow management. Who do not value their shareholders. Especially since they wanted to start phase 3 at the end of 2025. It was just a lie to the shareholders. The company is low on cash, but Carry takes the salary of a successful company with an approved drug on the market... Every month of delay without a process costs money for nothing. Some applications could have been submitted a long time ago.

0 · Reply

skyrockets_Inc May. 26 at 2:12 PM

$ADIL Added today. Running out of cash fast. They need to come up w/ some sort of strategic deal/financing quickly!

0 · Reply

ThatEscalatedQuickly May. 25 at 1:38 AM

$SBFM $GOVX $ADIL $FEMY I suppose the secret sauce is TRYING TO IDENTIFY THE PATTERNS and when do hedge funds flip leverage bearish or bullish in relation to r/s, shelf offering, warrants, stock price, etc. Its makes you REALIZE, ALL THE MOVES are made in the Cover of well times news releases. Retail is just chasing. Which is why i like TA set ups. Ill keep researching 13G filings 🤔

0 · Reply

ThatEscalatedQuickly May. 25 at 1:32 AM

$GOVX $ADIL $ADIL same thing 5/15/26 reduced exposure by -90% Armistice Capital 5B hedge fund. Then Adil rips after Armistice [*likely closes short position] $GOVX same 5/15/26 filing

0 · Reply

Mikemelga2024 May. 22 at 5:29 PM

$ADIL 🤦‍♂️🤦‍♂️🤦‍♂️

0 · Reply

BillionaireMotion May. 21 at 10:11 PM

You miss all the insane 400%+ squeezers ??! Make sure to keep ticker EZRA on watch ! Starting to make a move now.. I really hope the shorts get squeezed out hard. EZRA has 550k shares remaining to the public only . We saw a mini spike earlier.. Would not be shocked at all if it runs soon. Always try to buy early before the crowd does 🚀 💎 $AMPG $ADIL $FBYD $GCL long them all

1 · Reply

Zskylar May. 21 at 3:32 PM

$ADIL we going green??

1 · Reply

Mikemelga2024 May. 21 at 2:48 PM

$ADIL It needs to close in the green.

0 · Reply

Market Cap	5.06M
Revenue (ttm)	0.00
Net Income (ttm)	-7.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	21,500
Avg Vol	138,054
Day's Range	N/A - N/A
Shares Out	2.14M
Stochastic %K	68%
Beta	1.46
Analysts	Strong Sell
Price Target	$25.00